Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 2Pituitary Neoplasms 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Pituitary ACTH Hypersecretion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 10Paclitaxel 7Iodine-131 6Fluorodeoxyglucose F18 6Sorafenib 5vandetanib 4trametinib 4selpercatinib 4dabrafenib 4pembrolizumab 3fosbretabulin 3cabozantinib 3Vemurafenib 3Sunitinib 3Specimen Handling 3Nivolumab 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2romidepsin 2pazopanib 2lenvatinib 2combretastatin 2Trastuzumab 2Thyrotropin Alfa 2Ipilimumab 2Gefitinib 2FAPI-46 2Everolimus 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Rosiglitazone × Endocrine × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡